Regional Access NewBridge Pharmaceuticals specializes in bringing innovative therapies to the Middle East and Africa, offering sales opportunities by expanding regional market access through partnerships with global manufacturers seeking MENA and Africa presence.

Strategic Partnerships Leverage NewBridge’s established distribution, regulatory, and medical affairs capabilities to accelerate launches of oncology, hematology, immunology, neuroscience, metabolic and rare disease products across the region.

Growing Revenue With a revenue range of $10–$25 million and $60 million in funding, there is potential to scale commercial operations, expand product portfolios, and drive larger regional share for partner products.

Key Collaborations Recent/licensed distribution agreements with BioCryst and Pharming, plus MOUs with government health entities, indicate a proven track record of enabling regional commercialization which can be leveraged to onboard new products and exclusive rights.

Market Focus Target high-need therapeutic areas (oncology, hematology, immunology, neuroscience, metabolic and rare diseases) where regional access barriers exist, presenting clear opportunities for partners to address unmet medical needs and achieve faster market penetration.